Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment
Cancers · 21.07.2023 · 15 (14) · 3710
DOI: 10.3390/cancers15143710 ↗Kurz gefasst
Editorial in der Zeitschrift Cancers, online erschienen am 21.07.2023. Verfasst von Giovanni Vicidomini. Beteiligte Einrichtung: Thoracic Surgery Unit, Department of Translational Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer is a malignancy with a poor prognosis, with only 20% of patients having an overall survival longer than five years from diagnosis, and this prognosis has still not significantly improved despite developments in understanding the genetic evolution of lung cancer; improvements in the accuracy of diagnostic procedures; and refinements in the treatments with multimodal regimens, including surgery, radiotherapy and systemic therapy (chemotherapy, immunotherapy and targeted therapy) [...]
Autor:innen und Institutionen
- Thoracic Surgery Unit, Department of Translational Medicine, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
Zitieren
APA
Vicidomini, G. (2023). Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment. Cancers, 15(14), 3710. https://doi.org/10.3390/cancers15143710
Vancouver
Vicidomini G. Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment. Cancers. 2023;15(14):3710. doi:10.3390/cancers15143710
BibTeX
@article{Vicidomini2023,
author = {Vicidomini, Giovanni},
title = {Current Challenges and Future Advances in Lung Cancer: Genetics, Instrumental Diagnosis and Treatment},
journal = {Cancers},
year = {2023},
volume = {15},
number = {14},
pages = {3710},
doi = {10.3390/cancers15143710}
}
EUVIMED